Page last updated: 2024-09-05

lapatinib and Androgen-Independent Prostatic Cancer

lapatinib has been researched along with Androgen-Independent Prostatic Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
D'Abronzo, LS; Drake, CM; Ghosh, PM; Jathal, MK; Mooso, BA; Siddiqui, S; Steele, TM; Whang, YE	1

Other Studies

1 other study(ies) available for lapatinib and Androgen-Independent Prostatic Cancer

Article	Year
Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. British journal of cancer, 2019, Volume: 121, Issue:3 Topics: Animals; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms, Castration-Resistant; Protein Multimerization; Quinazolinones; Receptor, ErbB-2	2019

Article

Year

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.

British journal of cancer, 2019, Volume: 121, Issue:3

Topics: Animals; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms, Castration-Resistant; Protein Multimerization; Quinazolinones; Receptor, ErbB-2

2019